News

Treatment with Akero Therapeutics’ investigational efruxifermin led to reversals of compensated cirrhosis, or irreversible scarring in a still-functioning liver, among adults with metabolic dysfunction-associated…

Domenic Frappolli, who was born with biliary atresia, was named the American Liver Foundation’s (ALF) 2025 National LIVEr Champion. The foundation is spotlighting…

Researchers have discovered a key mechanism that allows the hepatitis B virus (HBV) to infect and persist in liver cells, in a new study…

Chemomab Therapeutics has aligned with the U.S. Food and Drug Administration (FDA) on the best path toward regulatory approval of its investigational therapy nebokitug,…

Researchers have developed a tool that can distinguish medications that result in cholestasis from those that don’t, based on their effects on key bile…

Long-term treatment with Rezdiffra (resmetirom) reduces liver scarring for most people with compensated cirrhosis, or irreversible scarring in a still-functioning liver, due to metabolic…

Researchers in China have identified six new mutations in the JAG1 and NOTCH2 genes as likely causes of Alagille syndrome. In…

A program using a telemedicine approach to treat hepatitis C in people with opioid use disorder that resulted in the cure of more than…

Gilead Sciences’ oral therapy seladelpar has been conditionally approved by the European Commission as a second-line therapy for adults with primary biliary…

A specific variant in the ABCB4 gene does not cause intrahepatic cholestasis of pregnancy (ICP) on its own, but it may increase the disease’s…